AMAG Pharmaceuticals Awards Four Grants to Support Preterm Birth and Preeclampsia Research
December 18 2019 - 08:00AM
As part of the company’s ongoing support of research to reduce
preterm birth and preeclampsia and associated complications, AMAG
Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced it has awarded
four grants totaling nearly $300,000 to independent researchers in
the field.
“Preterm birth is the leading cause of infant morbidity and
mortality, and over the past few years the March of Dimes report
card has shown that U.S. preterm birth rates have risen,” said
Brian Robinson, M.D., senior vice president of medical affairs at
AMAG. “Preeclampsia has also been increasing in the U.S and is a
major contributor to preterm birth, as well as maternal
complications, including mortality.i AMAG is committed to maternal
health and furthering research in this underserved area of
medicine.”
The 2019 grant recipients were selected by an independent
external review panel of maternal fetal medicine specialists with
extensive research experience. The panel was chaired by George
Saade, M.D., Professor, Obstetrics/Gynecology and Cell Biology at
The University of Texas Medical Branch.
“I continue to be impressed by the quality of applicants for
AMAG’s Research Grants Program, which is now in its sixth
consecutive year,” said Dr. Saade. “With AMAG’s contribution, this
research will provide clinicians with insights and knowledge to
better understand these conditions, which negatively impact
pregnancy and necessitate support for additional research.”
The following four investigators and studies have been awarded
grants:
- Jaipal Singh, Ph.D., Director at Indiana Center for Biomedical
Innovation at Indiana University School of Medicine and Jennifer
Sasser, Ph.D., Associate Professor at the University of Mississippi
Medical Center are both researching pharmacological and molecular
validation of dimethylarginine dimethylaminohydrolase as a
therapeutic target for preeclampsia;
- Rupsa C. Boelig, M.D., M.S. Assistant Professor Department of
Obstetrics and Gynecology, Division of Maternal and Fetal Medicine,
Walter K. Kraft, M.D. Professor, Department of Pharmacology and
Experimental Therapeutics, Leonard Edelstein, Ph.D. Assistant
Professor, Department of Medicine all of Thomas Jefferson
University are researching aspirin for prevention of preeclampsia:
individual determinants of platelet response and pregnancy
outcomes;
- Jennifer Condon, Ph.D., Associate Professor with Tenure in
collaboration with Gil Mor, M.D., Ph.D., Scientific Director, C.S.
Mott Center for Human Growth and Development, Vice Chair of
Research John M. Malone Jr., M.D. Endowed Professor, Department of
Obstetrics and Gynecology Wayne State University School of Medicine
both are researching targeting circulating GRP78 as a novel agent
to prevent preterm labor;
- Anum Minhas M.D., Cardiology Fellow, Allison Hays, M.D.,
Associate Professor of Medicine, Arthur Vaught, M.D., Assistant
Professor of Gynecology and Obstetrics and Sammy Zakaria, M.D.,
MPH, Assistant Professor of Medicine, Division of Cardiology
Department of Medicine all of Johns Hopkins Medicine will be
researching novel imaging methods to understand the association of
preeclampsia and cardiovascular disease.
About AMAGAMAG is a pharmaceutical
company focused on bringing innovative products to patients with
unmet medical needs. The company does this by leveraging its
development and commercial expertise to invest in and grow its
pharmaceutical products across a range of therapeutic areas,
including women’s health. For additional company information,
please visit www.amagpharma.com.
Forward-Looking Statements This
press release contains forward-looking information about AMAG
Pharmaceuticals, Inc. within the meaning of the Private Securities
Litigation Reform Act of 1995 and other federal securities laws.
Any statements contained herein which do not describe historical
facts, including, among others, beliefs that AMAG’s efforts will
further research and help doctors to better understand preterm
birth or preeclampsia are forward-looking statements which involve
risks and uncertainties that could cause actual results to differ
materially from those discussed in such forward-looking
statements.
Such risks and uncertainties include, among others, those risks
identified in AMAG’s filings with the U.S. Securities and Exchange
Commission (SEC), including its Annual Report on Form 10-K for the
year ended December 31, 2018, its Quarterly Report on Form
10-Q for the quarters ended March 31, 2019, June 30, 2019 and
September 30, 2019, and subsequent filings with the SEC, which are
available at the SEC’s website at www.sec.gov. Any such risks
and uncertainties could materially and adversely affect AMAG’s
results of operations, its profitability and its cash flows, which
would, in turn, have a significant and adverse impact on AMAG’s
stock price. AMAG cautions you not to place undue reliance on any
forward-looking statements, which speak only as of the date they
are made.
AMAG disclaims any obligation to publicly update or revise any
such statements to reflect any change in expectations or in events,
conditions or circumstances on which any such statements may be
based, or that may affect the likelihood that actual results
will differ from those set forth in the forward-looking
statements.
AMAG Pharmaceuticals® and the logo are registered trademarks
of AMAG Pharmaceuticals, Inc.AMAG Pharmaceuticals
Contacts: Investors: Linda Lennox908-627-3424
Media: Sarah Connors 781-296-0722
__________________________i Stevens W, Shih T, Incerti D, et al.
Short-term costs of preeclampsia to the United States health care
system. Am J Obstet Gynecol 2017
AMAG Pharmaceuticals (NASDAQ:AMAG)
Historical Stock Chart
From Feb 2024 to Mar 2024
AMAG Pharmaceuticals (NASDAQ:AMAG)
Historical Stock Chart
From Mar 2023 to Mar 2024